These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
42. Toll-like receptor 3 upregulation by type I interferon in healthy and scleroderma dermal fibroblasts. Agarwal SK; Wu M; Livingston CK; Parks DH; Mayes MD; Arnett FC; Tan FK Arthritis Res Ther; 2011 Jan; 13(1):R3. PubMed ID: 21223583 [TBL] [Abstract][Full Text] [Related]
43. Decreased interleukin-20 expression in scleroderma skin contributes to cutaneous fibrosis. Kudo H; Jinnin M; Asano Y; Trojanowska M; Nakayama W; Inoue K; Honda N; Kajihara I; Makino K; Fukushima S; Ihn H Arthritis Rheumatol; 2014 Jun; 66(6):1636-47. PubMed ID: 24470401 [TBL] [Abstract][Full Text] [Related]
47. Dersimelagon, a novel oral melanocortin 1 receptor agonist, demonstrates disease-modifying effects in preclinical models of systemic sclerosis. Kondo M; Suzuki T; Kawano Y; Kojima S; Miyashiro M; Matsumoto A; Kania G; Błyszczuk P; Ross RL; Mulipa P; Del Galdo F; Zhang Y; Distler JHW Arthritis Res Ther; 2022 Sep; 24(1):210. PubMed ID: 36050717 [TBL] [Abstract][Full Text] [Related]
48. 2-Methoxyestradiol inhibits bleomycin-induced systemic sclerosis through suppression of fibroblast activation. Zhu L; Song Y; Li M J Dermatol Sci; 2015 Jan; 77(1):63-70. PubMed ID: 25465161 [TBL] [Abstract][Full Text] [Related]
49. The involvement of leucine-rich α-2 glycoprotein in the progression of skin and lung fibrosis in bleomycin-induced systemic sclerosis model. Nakajima H; Nakajima K; Serada S; Fujimoto M; Naka T; Sano S Mod Rheumatol; 2021 Nov; 31(6):1120-1128. PubMed ID: 33535851 [TBL] [Abstract][Full Text] [Related]
50. Role of STAT3 in skin fibrosis and transforming growth factor beta signalling. Pedroza M; To S; Assassi S; Wu M; Tweardy D; Agarwal SK Rheumatology (Oxford); 2018 Oct; 57(10):1838-1850. PubMed ID: 29029263 [TBL] [Abstract][Full Text] [Related]
51. Imatinib mesylate reduces production of extracellular matrix and prevents development of experimental dermal fibrosis. Distler JH; Jüngel A; Huber LC; Schulze-Horsel U; Zwerina J; Gay RE; Michel BA; Hauser T; Schett G; Gay S; Distler O Arthritis Rheum; 2007 Jan; 56(1):311-22. PubMed ID: 17195235 [TBL] [Abstract][Full Text] [Related]
52. Loss of peroxisome proliferator-activated receptor gamma in mouse fibroblasts results in increased susceptibility to bleomycin-induced skin fibrosis. Kapoor M; McCann M; Liu S; Huh K; Denton CP; Abraham DJ; Leask A Arthritis Rheum; 2009 Sep; 60(9):2822-9. PubMed ID: 19714649 [TBL] [Abstract][Full Text] [Related]
53. The transcription factor GLI2 as a downstream mediator of transforming growth factor-β-induced fibroblast activation in SSc. Liang R; Šumová B; Cordazzo C; Mallano T; Zhang Y; Wohlfahrt T; Dees C; Ramming A; Krasowska D; Michalska-Jakubus M; Distler O; Schett G; Šenolt L; Distler JH Ann Rheum Dis; 2017 Apr; 76(4):756-764. PubMed ID: 27793816 [TBL] [Abstract][Full Text] [Related]
54. Growth differentiation factor 15, a marker of lung involvement in systemic sclerosis, is involved in fibrosis development but is not indispensable for fibrosis development. Lambrecht S; Smith V; De Wilde K; Coudenys J; Decuman S; Deforce D; De Keyser F; Elewaut D Arthritis Rheumatol; 2014 Feb; 66(2):418-27. PubMed ID: 24504814 [TBL] [Abstract][Full Text] [Related]
55. Unraveling the role of MiR-181 in skin fibrosis pathogenesis by targeting NUDT21. Mills TW; Wu M; Alonso J; Puente H; Charles J; Chen Z; Yoo SH; Mayes MD; Assassi S FASEB J; 2024 Sep; 38(17):e70022. PubMed ID: 39250282 [TBL] [Abstract][Full Text] [Related]
56. Increased expression of the transforming growth factor β-inducible gene HIC-5 in systemic sclerosis skin and fibroblasts: a novel antifibrotic therapeutic target. Piera-Velazquez S; Fertala J; Huaman-Vargas G; Louneva N; Jiménez SA Rheumatology (Oxford); 2020 Oct; 59(10):3092-3098. PubMed ID: 32442272 [TBL] [Abstract][Full Text] [Related]
57. Therapeutic interleukin-6 blockade reverses transforming growth factor-beta pathway activation in dermal fibroblasts: insights from the faSScinate clinical trial in systemic sclerosis. Denton CP; Ong VH; Xu S; Chen-Harris H; Modrusan Z; Lafyatis R; Khanna D; Jahreis A; Siegel J; Sornasse T Ann Rheum Dis; 2018 Sep; 77(9):1362-1371. PubMed ID: 29853453 [TBL] [Abstract][Full Text] [Related]
58. Baicalein alleviates fibrosis and inflammation in systemic sclerosis by regulating B-cell abnormalities. Peng B; Hu Q; He R; Hou H; Lian D; Chen Y; Li H; Song L; Gao Y; Chen T; Zhang G; Li J BMC Complement Med Ther; 2023 Feb; 23(1):62. PubMed ID: 36810081 [TBL] [Abstract][Full Text] [Related]
59. COA-Cl prevented TGF-β1-induced CTGF expression by Akt dephosphorylation in normal human dermal fibroblasts, and it attenuated skin fibrosis in mice models of systemic sclerosis. Nakai K; Karita S; Igarashi J; Tsukamoto I; Hirano K; Kubota Y J Dermatol Sci; 2019 Apr; 94(1):205-212. PubMed ID: 30954335 [TBL] [Abstract][Full Text] [Related]
60. Effect of Anti-S100A4 Monoclonal Antibody Treatment on Experimental Skin Fibrosis and Systemic Sclerosis-Specific Transcriptional Signatures in Human Skin. Trinh-Minh T; Györfi AH; Tomcik M; Tran-Manh C; Zhou X; Dickel N; Tümerdem BS; Kreuter A; Burmann SN; Borchert SV; Hussain RI; Hallén J; Klingelhöfer J; Kunz M; Distler JHW Arthritis Rheumatol; 2024 May; 76(5):783-795. PubMed ID: 38108109 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]